{"nctId":"NCT04051463","briefTitle":"Rhopressa for Corneal Edema Associated With Fuchs Dystrophy","startDateStruct":{"date":"2019-08-05","type":"ACTUAL"},"conditions":["Fuchs Endothelial Dystrophy"],"count":29,"armGroups":[{"label":"Netarsudil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Netarsudil Ophthalmic Solution"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Netarsudil Ophthalmic Solution","otherNames":["Rhopressa"]},{"name":"Placebo","otherNames":["Rhopressa vehicle without active ingredient"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.\n* Patient is able and willing to administer eye drops.\n* Patient is able to comprehend and has signed the Informed Consent form.\n\nExclusion Criteria:\n\n* Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.\n* Known sensitivity to any of the ingredients in the study medications.\n* Abnormal eyelid function.\n* History of herpetic keratitis.\n* History of non-compliance with using prescribed medication.\n* Current or planned pregnancy within the study duration.\n* Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.\n* Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Central Corneal Thickness","description":"Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23","spread":null},{"groupId":"OG001","value":"-2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Corrected Distance Visual Acuity (CDVA)","description":"Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["conjunctival hyperemia","ocular irritation","glare","lacrimation"]}}}